WO2010003304A1 - 产脱氧紫色杆菌素的重组菌及其应用 - Google Patents
产脱氧紫色杆菌素的重组菌及其应用 Download PDFInfo
- Publication number
- WO2010003304A1 WO2010003304A1 PCT/CN2009/000430 CN2009000430W WO2010003304A1 WO 2010003304 A1 WO2010003304 A1 WO 2010003304A1 CN 2009000430 W CN2009000430 W CN 2009000430W WO 2010003304 A1 WO2010003304 A1 WO 2010003304A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recombinant
- concentration
- bacillus
- gene cluster
- tryptophan
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 22
- OJUJNNKCVPCATE-AQTBWJFISA-N Deoxyviolacein Natural products O=C1NC(=C/C/1=C2/C(=O)Nc3ccccc23)c4c[nH]c5ccccc45 OJUJNNKCVPCATE-AQTBWJFISA-N 0.000 title abstract 9
- OJUJNNKCVPCATE-QGOAFFKASA-N deoxyviolacein Chemical compound C1=CC=C2C(C=3NC(C(/C=3)=C/3C4=CC=CC=C4NC\3=O)=O)=CNC2=C1 OJUJNNKCVPCATE-QGOAFFKASA-N 0.000 title abstract 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 35
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 31
- 108091008053 gene clusters Proteins 0.000 claims abstract description 28
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 28
- 241000588724 Escherichia coli Species 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 21
- 229960004799 tryptophan Drugs 0.000 claims abstract description 21
- 241000589776 Pseudomonas putida Species 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000002773 nucleotide Substances 0.000 claims abstract description 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 5
- 239000000758 substrate Substances 0.000 claims abstract description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 64
- 238000000855 fermentation Methods 0.000 claims description 21
- 230000004151 fermentation Effects 0.000 claims description 21
- 239000000411 inducer Substances 0.000 claims description 15
- 230000037361 pathway Effects 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 7
- 102000053602 DNA Human genes 0.000 claims description 6
- 238000003259 recombinant expression Methods 0.000 claims description 6
- 241000589516 Pseudomonas Species 0.000 claims description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 4
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- -1 n-octyl Chemical group 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 244000172533 Viola sororia Species 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000012634 fragment Substances 0.000 description 25
- 239000000049 pigment Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 235000005811 Viola adunca Nutrition 0.000 description 9
- 240000009038 Viola odorata Species 0.000 description 9
- 235000013487 Viola odorata Nutrition 0.000 description 9
- 235000002254 Viola papilionacea Nutrition 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 241000587482 Duganella sp. Species 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- XAPNKXIRQFHCHN-QGOAFFKASA-N violacein Chemical compound O=C\1NC2=CC=CC=C2C/1=C(C(=O)N1)/C=C1C1=CNC2=CC=C(O)C=C21 XAPNKXIRQFHCHN-QGOAFFKASA-N 0.000 description 4
- LEJQUNAZZRYZKJ-UHFFFAOYSA-N violacein Natural products Oc1ccc2NCC(C3=CC(=C4/C(=O)Nc5ccccc45)C(=O)N3)c2c1 LEJQUNAZZRYZKJ-UHFFFAOYSA-N 0.000 description 4
- 108010062877 Bacteriocins Proteins 0.000 description 3
- 241001277594 Duganella Species 0.000 description 3
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241000191025 Rhodobacter Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 101150002431 vioB gene Proteins 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000005730 Azoxystrobin Substances 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 240000000533 Capsicum pubescens Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- WFDXOXNFNRHQEC-GHRIWEEISA-N azoxystrobin Chemical compound CO\C=C(\C(=O)OC)C1=CC=CC=C1OC1=CC(OC=2C(=CC=CC=2)C#N)=NC=N1 WFDXOXNFNRHQEC-GHRIWEEISA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 244000000004 fungal plant pathogen Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical compound C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 1
- 229960005544 indolocarbazole Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001057 purple pigment Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 101150073925 vioA gene Proteins 0.000 description 1
- 101150061065 vioC gene Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Definitions
- the present invention relates to a recombinant strain producing deoxybacteria and its use.
- Violacein is a secondary metabolite produced by microorganisms. It belongs to an anthracene derivative and is a water-insoluble blue-violet pigment which is formed by oxidative condensation of two tryptophan molecules. Since the discovery of the purple bacillus in the late 19th century, people have explored a lot of their biological functions. In recent years, with the deepening of research, zeocin exhibits important biological activity and can be used as a potential anti-tumor and anti-virus. Drugs and bio-dyes have broad application prospects in the fields of textile printing and dyeing, plant pathogenic fungi control, viruses and cancer treatment. Therefore, they are receiving more and more attention.
- bacteriocin has the following biological activities: (1) It has a broad spectrum of antibacterial activity, such as anti-s taploylococcous aureus ⁇ Bacillus sp, streptococcus sp, myc obact eri urn, Neisserig, pseudomonas (Sanchez et al., Reevaluation) Of the Violacein Biosynthet ic Pathway and its Relat ionship to Indolocarbazole Biosynthesis. Journal 2006. 7, 1231-1240); (2) Antioxidant (Konzen et al., Antioxidant properties of violacein: possible relation on its biological funct ion. Journal 2006) . 14, 8307-8313); (3) Anti-tumor cells (de Carvalho et al.,
- Deoxyribomycin is a structural analog that is one less oxygen atom than purple bacillus and is a by-product of the azoxystrobin synthesis pathway, usually accompanied by the production of purple bacillus. Since the proportion of deoxy violet bacillus in blue-purple is small, it is equivalent to one tenth of the amount of purple bacillus, and it is difficult to isolate enough to study its properties and functions. And technology is still rarely studied. Due to its low yield, it is difficult to isolate pure deoxypurinin. There are few studies on the properties and biological activities of deoxy violet bacillus. At present, in addition to reporting that it can inhibit protozoa (Matz, C et al. Marine Biofi lm
- the recombinant strain producing deoxyi-biotin which is provided by the present invention is a recombinant strain obtained by introducing a gene cluster of deoxy violet bacillus synthesis into Escherichia coli BL21-CodonPlu S (DE3)-RIL or Pseudomonas putida.
- the recombinant bacteria can produce deoxy violet bacillus by fermentation with tryptophan as a substrate.
- the deoxyribomycin synthesis-related gene cluster is obtained by knocking out the oZ? gene in the purple bacillus synthesis gene cluster consisting of VioA, VioB, VioC, ioZ? and c ⁇ to obtain a recombinant gene cluster.
- the gene cluster is specifically a gene as follows 1) or 2) or 3):
- nucleotide sequence thereof is the DNA molecule of SEQ ID NO: 1 in the sequence listing;
- the DNA molecule in the step 3) has more than 75% homology with the DNA molecule of 1).
- the above stringent conditions can be carried out in a solution of 6XSSC, 0.5% SDS at 68 ° C, and then washed once with 2XSSC, 0.1% SDS and 1XSSC, 0.1% SDS.
- the deoxyribomycin synthesis-related gene clusters are also within the scope of the present invention.
- the gene cluster was introduced into the recombinant strain obtained by Escherichia coli BL21-CodonPlus(DE3)-RIL, and named as Escherichia coli BL-DV;
- Escherichia coli BL-DV was deposited on June 25, 2008 at the General Microbiology Center of China Microbial Culture Collection Management Committee (CGMCC, Address: Datun Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Zip Code 100101), Deposit The number is CGMCC No. 2557.
- the gene cluster was introduced into Pseudomonas sinensis as a recombinant strain obtained from mt-2 NCIMB 10432 and named as P. putida -VioADc
- An expression cassette containing the gene cluster and a recombinant expression vector containing the gene cluster or the expression cassette are also within the scope of the present invention.
- the method for producing deoxy violet bacillus in the present invention is to produce deoxy violet bacillus by fermentation using the recombinant Escherichia coli or the recombinant Pseudomonas putida using L-tryptophan as a substrate.
- the concentration of the L-tryptophan when the fermentation produces deoxyviocin, the concentration of the L-tryptophan may be 0.3-0.5 g/L fermentation medium, specifically 0.4 g/L.
- the fermentation temperature may be 10-37 ° C, specifically 20 ° C.
- the Escherichia coli BL-DV CGMCC No. 2557 of the present invention can use IPTG as an inducer, and the concentration of IPTG can be 0 ⁇ ol/L ⁇ 0. 7-1. 3mmol / L, specifically 1. 0ramol / L.
- the fermentation medium of the fermentation medium may be 0. 3-0. 5g / L fermentation medium, specific In the fermentation production of 0.4 g/L 0 , the fermentation medium may be any medium for providing the growth of Pseudomonas putida, specifically NaH 2 P0 4 ⁇ 2H 2 0 1. 0-2, 0 g / L, Na 2 HP0 4 ⁇ 12H 2 0 3. 0-4. 0 g/L, NH 4 C1 0. 5-1. 0 g/L, K2HPO4 ⁇ 3H 2 0 7.
- the solvent is water.
- an inducer is added to the recombinant bacteria.
- the inducing agent selected as necessary, 3. / Wii ⁇ -VioAD present invention can be used n-alkanes or more carbon atoms as an inducer of six, in particular n-octyl embankment, the concentration of n-octane is specifically 0.05 Ml/100 ml medium.
- the fermentation temperature is specifically 20 °C.
- Figure 1 shows the clusters of overlapping extension PCR recombinant deoxy violet bacillus synthesis.
- Fig. 2 shows the results of PCR amplification of the fragments A, B, C and D of the purple bacillus synthesis-related gene cluster.
- Fig. 3 is a diagram showing the results of high performance liquid chromatography identification of the pigment produced by the recombinant strain BL-DV.
- Figure 4 is a graph showing the results of high performance liquid chromatography identification of the pigment produced by the recombinant strain P. putida-VioAD. The best way to implement the invention
- Example 1 Recombinant bacteria producing deoxy violet bacillus
- the genus Duganella sp. B2 CGMCC Ns2056 was transferred to a liquid medium (starch 15 g / L, ferrous sulfate 0. 03g / L, potassium nitrate lg / L, dipotassium hydrogen phosphate 0. 7g / L, Magnesium sulphate 0. 5g / L, tryptophan 0. 5g / L, pH adjustment of 7. 0), 25 °C, 200rpra culture for 36 hours, according to the Shanghai Biotech genomic DNA extraction kit instructions for the extraction of Rhodobacter B2 Genomic DNA.
- the amplified fragments A and B use the PCR program I in Table 2, and the amplified fragment C uses the PCR program in Table 2
- the PCR product fragments B and C were mixed in a volume ratio of 1:1 and then diluted 10-fold as a template for further PCR amplification.
- the PCR reaction system was 50 L, and the above mixture containing the fragment C was 1. 5 L 2. 5 U TaKaRa Pfu DNA polymerase.
- the PCR reaction procedure is PCR program III, when the second step is completed. The program was stopped, and 25 pmol of P3 and P6 primers were added to the reaction system, followed by steps 3 and 4 of PCR procedure III, and fragments B and C were ligated together to form fragment D (Fig. 1). Fragment D was purified by PCR product kit, and fragment D was cloned into pMD18-T vector to obtain
- the PMD18-T-D vector, sequencing, and sequencing results showed that the nucleotide sequence of fragment D is in the sequence of sequence 1 from the 5' end of 3058-6198.
- the pMD18-TD vector and the Nde I and Xhol I double-digestion expression vector pET30a were digested with e I and ⁇ 3 ⁇ 4 ⁇ I, and the 3057 bp fragment A, 3140 bp fragment D and pET30a vector enzyme were recovered. After the excision of the large fragment, the three fragments recovered above were ligated under the action of T4 DNA ligase to construct a recombinant expression vector pET30aVioAD.
- the recombinant expression vector pET30aVioAD was transformed into E. coli DH5 ⁇ competent cells, and the transformed product was applied to LB plates containing ampicillin (100 g/ml).
- the transformants were picked and cultured, and the plasmid was extracted by alkaline lysis.
- the positive clones were sequenced, and the sequencing results showed that the nucleotide sequence of the VioAD fragment is shown in SEQ ID NO:1 in the sequence listing, and the sequence 1 is from the 5-1308 position at the 5' end to the VioA gene, which encodes VioA in the purple bacillus synthesis pathway.
- the enzyme from the 5' end, at positions 1305-4322, is the VioB gene, which encodes the VioB enzyme in the purple bacillus synthesis pathway; the 4233-5612 from the 5' end is the VioC gene, which encodes the VioC enzyme in the purple bacillus synthesis pathway; From the 5' end, 5622-6197 is the VioE gene, which encodes the VioE enzyme in the purple bacillus synthesis pathway.
- the VioD gene is not contained in the VioAD fragment.
- the VioAD is a cluster of genes related to deoxy violet bacillus synthesis.
- Double digestion of pMD18-T-D vector and I and 5k7 I double-digestion expression vector pCOMlO (Smits THM et al., New alkane-responsive expression) with se I and TVoi I double digestion fragment A, Not I and T/WI Plasmids for E. coli and Pseudomonas. Plasmid 2001. 46, 16 - 24. ) (Tsinghua University) Recover 3057 bp fragment A, 3140 bp fragment D and pCOMlO vector-digested large fragment, and the above recovered three fragments are The recombinant expression vector pC0M10VioAD was constructed by ligation of T4 DNA ligase.
- the culture medium concentration at 0 °C was 0.77, and 0. ImM IPTG was added.
- the correct expression of the four enzymes indicates that the deoxyribomycin synthesis gene cluster may contain rare codons, and the A coli BL21- CodonPlus (DE3) - RIL- VioAD producing deoxy violet bacillus is named Escherichia coli BL-DV;
- the blue-purple ethanol solution of the BL-DV solution was dissolved in 100% methanol for high performance liquid chromatography analysis using an Agilent-1100 high performance liquid chromatograph.
- the column was Agi lent Ecl ipse XDB-C18.
- 150mm X 4 should be, 5 m ; column temperature 30 ° C; eluent is 70% by volume aqueous methanol solution; flow rate 1. 0 mL / min; detection wavelength: 570 nm.
- Fig. 3 I: high performance liquid chromatogram of the pigment produced by Duganella sp. B2 CGMCC N22056, the first peak is purple bacillus, the second peak is deoxy violet bacillus; II: recombinant bacteria BL High-performance liquid chromatogram of crude pigment extracted from -DV.
- E. coli BL-DV was deposited on June 25, 2008 at the General Microbiology Center of China Microbial Culture Collection Management Committee (CGMCC, Address: Datun Road, Chaoyang District, Beijing, China) Institute of Microbiology, National Academy of Sciences, Zip Code 100101), with accession number CGMCC No. 2557.
- CGMCC General Microbiology Center of China Microbial Culture Collection Management Committee
- pCOMlOVioAD Transfer the recombinant vector pCOMlOVioAD to Pseudomonas putida mt-2 NCIMB 10432 to obtain recombinant corpse.
- P. putida -VioAD and P. /?i/iii/a-pC0M10 were cultured in LB medium at 37 ° C for bacterial concentration 0D 6 , respectively . . 0 ⁇ 0. 0 ⁇ The percentage of the volume is 0. 05% ⁇ ⁇ , induced at 20 ° C for 30h. Centrifuge 50 mL of the fermentation broth at 7000 X g for 10 min, discard the supernatant, add the same volume of deionized water to the precipitate, mix it with a vortex mixer, centrifuge at 7000 X g for 10 min, then add none.
- P. putida -VioAD blue ethanol solution was distilled under reduced pressure in 100% methanol for high performance liquid chromatography analysis using Agi lent-1100 high performance liquid chromatography, column % Agi lent Ecl ipse XDB- C18 , 150 mm X 4mra, 5 ⁇ m; column temperature 30 ° C; eluent is 70% by volume aqueous methanol solution; flow rate 1. 0 mL / min; detection wavelength: 570 nra.
- the results of high performance liquid chromatography were as shown in Fig. 4.
- the blue substance in the ethanol solution of the auxiliary P. putida-VioAD was consistent with the retention time of the deoxy violet bacillus of the Dugarwlla B2 purple bacillus byproduct. 9min), and only one peak.
- the blue substance in the ethanol solution of put - VioAO is deoxy violet bacillus, recombinant Pseudomonas putida.
- -VioAD can express VioA, VioB, VioC and VioE in the purple bacillus synthesis pathway, which can be synthesized. Deoxy violet bacillus.
- Fig. 4 I: high performance liquid chromatogram of the pigment produced by Duganel la sp. B2 CGMCC Ns2056, the first peak is purple bacillus, the second peak is deoxy violet bacillus; II: A wiii a - High performance liquid chromatogram of the pigment produced by VioAD.
- Example 2 Recombinant bacteria produce deoxy violet bacillus
- Recombinant Bacterium BL-DV CGMCC No. 2557 produces deoxy violet bacillus
- BL-DV CGMCC No. 2557 L-tryptophan, cell concentration (0D 6 value) when adding inducer (IPTG), amount of inducer, induction time 4 factors as test factors, deoxidation
- IPTG inducer
- induction time 4 factors as test factors
- deoxidation The purple bacillus production was used as an indicator, and the above four factors were subjected to an orthogonal test of 4 factors and 3 levels, and the results are shown in Table 3.
- the pigment was extracted in the same manner as in Example 1.
- the pigment concentration was measured by measuring the absorbance of the pigment in ethanol solution at the maximum absorption wavelength.
- the deoxy violet bacillus produced by Duganella sp B2 was measured at a wavelength of 562 nm, and anhydrous ethanol was used as a blank control.
- the corresponding pigment concentration value is obtained by the absorbance value-pigment concentration standard curve, and each test is repeated 3 times, and the average value is obtained, and the obtained light absorption coefficient ⁇ is 9. 0955 1 ⁇ g- 1 ⁇ cm"O
- the sulphate Duganella sp. B2 CGMCC NQ 2056 is added to the liquid medium (starch 15g / L, ferrous sulfate 0. 03g / L, potassium nitrate lg / L, dipotassium hydrogen phosphate 0. 7g / L, The magnesium sulfate was 0.5 g/L, the tryptophan was 0.5 g/L, the pH was 7.0 g, and the cells were cultured at 25 ° C for 30 hours, and the cells were collected by centrifugation, and the cells were extracted with ethanol to obtain a blue-violet substance.
- B2 CGMCC No2056 produced deoxygenation of violet bacillus for quantitative analysis.
- Quantitative analysis was carried out by measuring the absorbance of the blue-violet substance (pigment) in ethanol at the maximum absorption wavelength.
- the deoxy violet bacillus produced by Duganel la sp B2 was measured at a wavelength of 562 nm, using anhydrous ethanol as a blank control, and the absorbance value was passed.
- the pigment concentration standard curve obtains the corresponding pigment concentration value, and each experiment is repeated 3 times, and the average value is obtained, and the obtained absorption coefficient ⁇ is 14.
- Deoxyribomycin is a by-product of the purple bacillus synthesis pathway, which usually has a low yield and is difficult to separate and cannot be scaled up and applied.
- Escherichia coli BL-DV CGMCC No. 2557 and P. putida-VioAD of the present invention produce higher yield of deoxy violet bacillus; Escherichia coli BL-DV CGMCC No. 2557 can reach 0. 17g / L fermentation broth, P. put i da -VioAD can be reached in the usual shake flask culture to achieve 1. 5g / L fermentation broth, and easy to extract, separation and purification is simple.
- the recombinant strain of the present invention is Escherichia coli or Pseudomonas putida, which is convenient to control and convenient for industrial production. _
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0910514A BRPI0910514A2 (pt) | 2008-07-11 | 2009-04-22 | bactérias recombinantes para produção de deoxiviolaceína e seus usos. |
JP2011516946A JP5632370B2 (ja) | 2008-07-11 | 2009-04-22 | デオキシビオラセインを産生する組み換え細菌及びその使用 |
GB1100438.9A GB2473401B (en) | 2008-07-11 | 2009-04-22 | Recombinant bacteria for producing deoxyviolacein and uses thereof |
CN2009801258713A CN102099477A (zh) | 2008-07-11 | 2009-04-22 | 产脱氧紫色杆菌素的重组菌及其应用 |
US13/003,227 US8778654B2 (en) | 2008-07-11 | 2009-04-22 | Recombinant bacteria for producing deoxyviolacein and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101166013A CN101319219B (zh) | 2008-07-11 | 2008-07-11 | 一种生产脱氧紫色杆菌素的方法及其专用重组菌 |
CN200810116601.3 | 2008-07-11 | ||
CN200810224359.1 | 2008-10-17 | ||
CN2008102243591A CN101368169B (zh) | 2008-10-17 | 2008-10-17 | 产脱氧紫色杆菌素的重组恶臭假单孢菌及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010003304A1 true WO2010003304A1 (zh) | 2010-01-14 |
Family
ID=41506661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000430 WO2010003304A1 (zh) | 2008-07-11 | 2009-04-22 | 产脱氧紫色杆菌素的重组菌及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8778654B2 (zh) |
JP (1) | JP5632370B2 (zh) |
CN (1) | CN102099477A (zh) |
BR (1) | BRPI0910514A2 (zh) |
GB (1) | GB2473401B (zh) |
WO (1) | WO2010003304A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012053985A1 (en) * | 2010-10-22 | 2012-04-26 | Kemijski inštitut | Improved synthesis of biosynthetic product by ordered assembly of biosynthetic enzymes guided by the nucleotide sequence motif template |
US8778654B2 (en) | 2008-07-11 | 2014-07-15 | Tsinghua University | Recombinant bacteria for producing deoxyviolacein and uses thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101602772B1 (ko) | 2014-03-05 | 2016-03-14 | 대한민국 | 비올라세인을 생산하는 마실리아 속 신규 미생물 ep15224 |
GB2537144B (en) * | 2015-04-09 | 2019-11-13 | Glen Hastie Nugent David | Method of dyeing fabric using microorganisms |
KR102006904B1 (ko) * | 2017-07-07 | 2019-08-02 | 울산과학기술원 | 디옥시바이오라세인 생산능이 향상된 재조합 미생물 및 그를 이용한 디옥시바이오라세인을 생산하는 방법 |
CN110643651B (zh) * | 2019-09-30 | 2022-11-04 | 大连民族大学 | 一种促进紫色色杆菌中脱氧紫色杆菌素表达的方法 |
KR102404998B1 (ko) * | 2019-12-20 | 2022-06-07 | 씨제이제일제당 주식회사 | 다중약물 유출펌프 변이체, 상기 변이체를 코딩하는 폴리뉴클레오티드, 상기 변이체를 포함하는 미생물, 및 이를 이용하여 비올라세인 또는 디옥시비올라세인을 제조하는 방법 |
KR102370964B1 (ko) * | 2019-12-20 | 2022-03-10 | 씨제이제일제당 주식회사 | 다중약물 수송체의 활성을 증가시키는 유전적 변형을 포함하는 미생물, 및 그를 이용한 트립토판 대사체의 생산 방법 |
CN111748564B (zh) * | 2020-07-13 | 2022-07-22 | 新乡医学院 | 经过遗传改造的紫色杆菌素生物合成基因簇、重组表达载体、工程菌及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002050299A2 (de) * | 2000-12-20 | 2002-06-27 | Stiftung Alfred-Wegener-Institut Für Polar- Und Meeresforschung | Mikrobiologisches verfahren zur biosynthese der natürlichen blau-violetten farbstoffe violacein und desoxyviolacein und deren verwendung |
CN101139654A (zh) * | 2007-07-26 | 2008-03-12 | 曹传东 | 一种以硫铁矿为原料生产铁精砂粉的方法及其设备 |
CN101319219A (zh) * | 2008-07-11 | 2008-12-10 | 清华大学 | 一种生产脱氧紫色杆菌素的方法及其专用重组菌 |
CN101368169A (zh) * | 2008-10-17 | 2009-02-18 | 清华大学 | 产脱氧紫色杆菌素的重组恶臭假单孢菌及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101319213B (zh) * | 2007-06-07 | 2010-10-20 | 上海市血液中心 | 细菌基因组dna抽提液及其制备方法和应用 |
CN101139564B (zh) * | 2007-08-08 | 2010-06-09 | 清华大学 | 一株杜擀氏菌及其应用 |
US8778654B2 (en) | 2008-07-11 | 2014-07-15 | Tsinghua University | Recombinant bacteria for producing deoxyviolacein and uses thereof |
-
2009
- 2009-04-22 US US13/003,227 patent/US8778654B2/en not_active Expired - Fee Related
- 2009-04-22 GB GB1100438.9A patent/GB2473401B/en not_active Expired - Fee Related
- 2009-04-22 JP JP2011516946A patent/JP5632370B2/ja not_active Expired - Fee Related
- 2009-04-22 CN CN2009801258713A patent/CN102099477A/zh active Pending
- 2009-04-22 WO PCT/CN2009/000430 patent/WO2010003304A1/zh active Application Filing
- 2009-04-22 BR BRPI0910514A patent/BRPI0910514A2/pt not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002050299A2 (de) * | 2000-12-20 | 2002-06-27 | Stiftung Alfred-Wegener-Institut Für Polar- Und Meeresforschung | Mikrobiologisches verfahren zur biosynthese der natürlichen blau-violetten farbstoffe violacein und desoxyviolacein und deren verwendung |
CN101139654A (zh) * | 2007-07-26 | 2008-03-12 | 曹传东 | 一种以硫铁矿为原料生产铁精砂粉的方法及其设备 |
CN101319219A (zh) * | 2008-07-11 | 2008-12-10 | 清华大学 | 一种生产脱氧紫色杆菌素的方法及其专用重组菌 |
CN101368169A (zh) * | 2008-10-17 | 2009-02-18 | 清华大学 | 产脱氧紫色杆菌素的重组恶臭假单孢菌及其应用 |
Non-Patent Citations (2)
Title |
---|
BRADY SF ET AL.: "Cloning and heterologous expression of a natural product biosynthetic gene cluster from eDNA", ORG. LETT., vol. 3, no. 13, 28 June 2001 (2001-06-28), pages 1981 - 1984 * |
WANG HAISHENG ET AL.: "Recent research progress of bacterial violacein", CHEMICAL INDUSTRY AND ENGINEERING PROGRESS, vol. 27, no. 3, 31 March 2008 (2008-03-31), pages 315 - 321 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8778654B2 (en) | 2008-07-11 | 2014-07-15 | Tsinghua University | Recombinant bacteria for producing deoxyviolacein and uses thereof |
WO2012053985A1 (en) * | 2010-10-22 | 2012-04-26 | Kemijski inštitut | Improved synthesis of biosynthetic product by ordered assembly of biosynthetic enzymes guided by the nucleotide sequence motif template |
Also Published As
Publication number | Publication date |
---|---|
GB2473401B (en) | 2012-10-17 |
US8778654B2 (en) | 2014-07-15 |
CN102099477A (zh) | 2011-06-15 |
JP5632370B2 (ja) | 2014-11-26 |
GB201100438D0 (en) | 2011-02-23 |
JP2011527183A (ja) | 2011-10-27 |
BRPI0910514A2 (pt) | 2015-09-22 |
US20110183384A1 (en) | 2011-07-28 |
GB2473401A (en) | 2011-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010003304A1 (zh) | 产脱氧紫色杆菌素的重组菌及其应用 | |
KR101814888B1 (ko) | 5-아미노레불린산 고수율 균주 및 이의 제조방법과 응용 | |
CN110791493B (zh) | 一种天冬氨酸氨裂合酶突变体及其应用 | |
CN109055327B (zh) | 醛酮还原酶突变体及其应用 | |
US10053682B2 (en) | β-galactosidase mutant with high transglycosidase activity, and preparation method thereof and uses thereof | |
WO2019228083A1 (zh) | 羰基还原酶突变体及其在环戊二酮类化合物还原中的应用 | |
CN109504645B (zh) | 异亮氨酸双加氧酶、突变体及在合成4-羟基异亮氨酸中的应用 | |
CN111235123B (zh) | 一种醇溶液高浓度耐受的羰基还原酶及其应用 | |
CN106754775A (zh) | 一种羰基还原酶突变体及其基因与应用 | |
CN113308443A (zh) | 一种红曲霉单加氧酶突变体及其应用 | |
CN109022515B (zh) | 一种6-o-去甲罂粟碱的生物催化制备方法 | |
CN108998401B (zh) | 一种生产3-氨基异丁酸的方法 | |
CN107586762A (zh) | 一种3‑甾酮‑δ1‑脱氢酶突变体及其应用 | |
CN110904062B (zh) | 一株高产l-丙氨酸的菌株 | |
WO2024138928A1 (zh) | 半乳糖-1-磷酸尿苷酰基转移酶突变体及其在制备l-赖氨酸中的应用 | |
KR20200040585A (ko) | 고활성의 말산 탈수소효소가 도입된 숙신산 생성용 변이 미생물 및 이를 이용한 숙신산 제조방법 | |
CN112225781B (zh) | 一种表达新型冠状病毒n蛋白的方法 | |
CN110016458B (zh) | 一种发酵合成α-红没药醇的工程菌株及其构建方法 | |
CN110438055B (zh) | 一种含有苯丙酮酸脱羧酶突变体的全细胞催化剂及在生产苯乙醇中的应用 | |
CN113061590A (zh) | 藻毒素降解酶及复合材料与应用 | |
JP2013132226A (ja) | (−)−3a,6,6,9a−テトラメチルドデカヒドロナフト[2,1−b]フランの製造方法 | |
WO2020107781A1 (zh) | 一种酶法拆分制备(s)-1,2,3,4-四氢异喹啉-3-甲酸的方法 | |
CN112680454B (zh) | 一种人干扰素-κ的生产方法 | |
US20240301454A1 (en) | Method for Producing Phycocyanobilin Using a Recombinant Escherichia Coli | |
Pengyan et al. | Expression and Optimizated of Liraglutide Precursor Peptide, GLP-1 (7-37) K34R, in Escherichia coli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980125871.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09793779 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 1100438 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20090422 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1100438.9 Country of ref document: GB |
|
ENP | Entry into the national phase |
Ref document number: 2011516946 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 940/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13003227 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09793779 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: PI0910514 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110110 |